Financial Survey: Silexion Therapeutics (NASDAQ:SLXN) versus DBV Technologies (NASDAQ:DBVT)

Silexion Therapeutics (NASDAQ:SLXN) and DBV Technologies (NASDAQ:DBVT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership and dividends.

Earnings and Valuation

This table compares Silexion Therapeutics and DBV Technologies”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silexion Therapeutics	N/A	N/A	$260,000.00	N/A	N/A
DBV Technologies	$15.73 million	5.59	-$72.73 million	($4.50)	-0.95

Silexion Therapeutics has higher earnings, but lower revenue than DBV Technologies.

Profitability

This table compares Silexion Therapeutics and DBV Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Silexion Therapeutics	N/A	N/A	-249.43%
DBV Technologies	-815.73%	-106.07%	-76.17%

Risk and Volatility

Silexion Therapeutics has a beta of 0.11, meaning that its stock price is 89% less volatile than the S&P 500. Comparatively, DBV Technologies has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Silexion Therapeutics and DBV Technologies, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silexion Therapeutics	0	0	1	0	3.00
DBV Technologies	0	0	2	0	3.00

Silexion Therapeutics presently has a consensus price target of $9.00, suggesting a potential upside of 576.69%. DBV Technologies has a consensus price target of $22.50, suggesting a potential upside of 426.07%. Given Silexion Therapeutics’ higher probable upside, equities analysts clearly believe Silexion Therapeutics is more favorable than DBV Technologies.

Institutional and Insider Ownership

10.9% of Silexion Therapeutics shares are owned by institutional investors. Comparatively, 71.7% of DBV Technologies shares are owned by institutional investors. 33.0% of Silexion Therapeutics shares are owned by company insiders. Comparatively, 1.9% of DBV Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

About Silexion Therapeutics

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.

About DBV Technologies

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. The company’s earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.